CHEMOGENICS BIOPHARMA, LLC

ChemoGenics Biopharma, LLC specializes in custom small molecule synthesis and bioanalytical services for biomedical research initiatives, with a focus on developing inhibitors of physiological methyltransferases. The company leverages advanced organic chemistry techniques and analytical platforms to support drug discovery pipelines, delivering high-purity compounds and rigorous pharmacokinetic/pharmacodynamic characterization for internal and collaborative projects. Their technical expertise spans synthetic route design, mid-to-late-stage chemical optimization, LC-MS/MS bioanalysis, and target engagement validation—key capabilities critical to advancing novel therapeutics in epigenetic and metabolic disease spaces. What distinguishes ChemoGenics is its niche focus on challenging methyltransferase targets, requiring precise stereochemical control and low-volume, high-complexity synthesis under tightly controlled conditions. The contractor has demonstrated direct engagement with the Department of Health and Human Services, specifically supporting programs under the National Center for Advancing Translational Sciences (NCATS). This relationship reflects a focused partnership in early-stage drug development, where rapid, high-quality chemical delivery and analytical validation are essential to accelerating preclinical innovation. ChemoGenics operates primarily under NAICS 541380, which encompasses specialized testing laboratories and services for pharmaceutical and biotech research. Their market positioning centers on the translational research segment, serving government-funded initiatives that require bespoke chemical synthesis beyond commercial catalog availability. They are not a broad-service CRO but a precision chemistry partner for high-value, low-volume projects in epigenetic drug discovery. As a small business structured as a 2J entity based in Durham, North Carolina, ChemoGenics Biopharma, LLC maintains a lean, mission-driven operational model. While currently unaffiliated with formal government certifications such as 8(a), HUBZone, or WOSB, its geographic presence in a major biotech corridor enhances access to academic and federal research ecosystems. The company’s positioning is that of a specialized, agile provider for mission-critical chemical development in public health innovation.